PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 1, 2004Annals of Clinical Psychiatry139 citations

Modafinil: Preclinical, Clinical, and Post-Marketing Surveillance—A Review of Abuse Liability Issues

View Full Paper
HMHugh MyrickRMRobert MalcolmBTBrent R. Taylor

Key Points

Key points are not available for this paper at this time.

Abstract

Modafinil is an agent that is frequently used in the treatment of narcolepsy. More recently it has been used in the treatment of a variety of psychiatric, neurological, and medical illnesses. Due to its ability to improve wakefulness, modafinil has been viewed as a stimulant. Based on the potential for modafinil to become widely used in a variety of syndromes and settings, evidence from preclinical in vitro and in vivo studies, human laboratory studies, and post-marketing experiences examining the potential abuse liability of modafinil were reviewed. Initial evidence suggests that modafinil has limited potential for large-scale abuse.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Myrick et al. (2004) studied this question.

synapsesocial.com/papers/6a6c11a147a1bfb288f3642ahttps://doi.org/10.1080/10401230490453743
Ask AI
Helpful
Bookmark
Share
View Full Paper